Search

HDDC Spring Symposium – Tuesday, June 7, 2022 Enders Building Folkman Auditorium (In person) and Virtually 9am – 5 PM 9-9:15am Welcome and introduction Sensory-motor regulation of gut functions 9:15-9:45AM Irene Miguel Aliaga (MRC – Imperial College London) 9:45-10:15AM Amber Alhadeff 10:15-10:30...

While gene therapy is not yet widely available for inherited retinal disorsers (IRDs), researchers are making exciting discoveries, and the future looks more promising than ever before. In this issue of eye Insights, we provide a look into current offerings in gene therapy, and a glimpse into the...

Inherited retinal disorders are rare, hereditary disorders caused by mutations in genes that encode proteins needed for normal retinal health and function. The first gene associated with retinitis pigmentosa was identified at Mass Eye and Ear in 1990, and since then, over 250 IRD-causing genes have...

The first gene-augmentation therapy for an IRD was approved by the U.S. Food and Drug Administration (FDA) in December 2017 after nearly two decades of development in preclinical models and clinical trials. The drug, known as Luxturna®, is for individuals with autosomal recessive retinal dystrophies...